In the present article, we confirmed this speculation, and the results showed that the knockdown of RPL21 expression by siRNAs (siL21-1 and siL21-2) significantly inhibited the growth of human PC cells in vitro and in vivo, which suggested that RPL21 is potentially an effective therapeutic target for PC. This evidence concerns the gene RPL21 and pachyonychia congenita.